Study Highlights The Growth Of Human Triple Negative Breast Cancers

According to a recent study, researchers talked about preventing the development of triple negative breast cancer. Read on.

Navya Kharbanda
Written by: Navya KharbandaUpdated at: Nov 29, 2022 19:20 IST
Study Highlights The Growth Of Human Triple Negative Breast Cancers

According to a new study, that appeared online in the journal Nature Communications, researchers from Boston University Chobanian & Avedisian School of Medicine have shown that appropriate control of a cellular path, called the Hippo pathway can prevent the development of triple-negative breast cancer. The alternate name of triple-negative break cancers is Basal-like breast cancers. These cancers are a specifically aggressive subtype of breast cancer that has a limited set of treatment options. The origin of development of cells that are present on the surface of the breast duct and basal types of breast cancer is not clear, but certain studies suggest that basal subtype cancers can develop because of luminal epithelial cells.

Corresponding author Bob Varelas, PhD, associate professor of biochemistry, "We found that when this pathway is dysregulated or impaired, luminal epithelial cells in the mammary gland rapidly transition to a basal-like state and develop into triple negative carcinomas."

Also read: Breast Cancer Awareness Month: 7 Tips To Maintain Healthy Breasts To Prevent Breast Cancer

As per the researchers, the gene-expression signature detected from Lats1/2-deleted tumors can be helpful for identifying aggressive symptoms linked to triple negative breast cancers. It is well known that basal-like breast cancers are quite difficult to treat, the co-authpr Varelas hopes that these findings will prove to be helpful in providing fresh guidance and directions for improved treatment options and better results for patients. He added, "A better understanding of the cellular mechanisms leading to the development of these cancers is essential to identifying new therapeutic options."

Disclaimer